Europe
Bavarian Nordic A/S announced that the Data and Safety Monitoring Board confirmed a partial response in one of the first chordoma patients recruited and treated with the combination of BN-Brachyury and radiation treatment at the first evaluation timepoint.
Evotec SE announced that its strategic alliance with Celgene Corporation has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec.
InflaRx reported the top-line results of the international SHINE Phase IIb study, investigating the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody, in patients suffering from moderate to severe Hidradenitis Suppurativa (HS), a painful and debilitating chronic inflammatory skin disease with limited treatment options.
Service agreement gives Servier access to Yposkesi’s robust production capacity
Heidelberg Pharma AG announced that it has received a milestone payment of 250 TUSD from its cooperation partner Telix Pharmaceuticals Limited, Melbourne, Australia,.
Companies from across the globe share updates on their pipelines and growth strategies.
GENFIT announced the launch of a P2 clinical trial evaluating elafibranor’s activity on liver fat quantity and – most importantly – fat composition in nonalcoholic fatty liver disease (NAFLD) patients.
Yukin Therapeutics, a French company specializing in the development of new molecules for cancer treatment, has completed a €3.3 million financing round for the development and optimization of its proprietary therapeutic molecules.
Minoryx Therapeutics announces that the first patient has been dosed with its lead candidate, leriglitazone, in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia.
Epigenomics AG announced that company management will be presenting at the Raymond James Life Sciences and MedTech Conference in New York on Tuesday, June 18, 2019, at 1:50 pm / 7:50 pm and invites investors to participate by webcast.
PRESS RELEASES